DEA Moves to Ban Gas-Station Antidepressant
Published Date: 7/8/2026
Proposed Rule
Summary
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 4 costs, 1 mixed.
Tianeptine Proposed for Schedule I
The DEA proposes to place tianeptine in Schedule I, which would subject anyone who handles or uses tianeptine to the strict controls that apply to the most tightly regulated drugs. If finalized, handling tianeptine (manufacture, distribution, research, import/export, or possession) would trigger administrative, civil, and criminal sanctions applicable to Schedule I substances.
Retail Sales and Possession Made Unlawful
Retail sales of Schedule I controlled substances to the general public are not allowed, and possession of any quantity of tianeptine in a manner not authorized by the Controlled Substances Act would be unlawful and subject to prosecution. Persons who handle tianeptine without authorization may face administrative, civil, or criminal sanctions.
New Registration and Compliance Duties
Anyone who manufactures, distributes, imports, exports, researches, or otherwise handles tianeptine would need to register with DEA and comply with Schedule I rules. Required controls include DEA registration, security and screening requirements, labeling and packaging rules, quotas for manufacture, inventory requirements, recordkeeping and reporting, order-form compliance, and import/export controls.
Surrender or Dispose Stocks If Not Registered
Persons unwilling or unable to obtain a Schedule I registration must surrender or transfer all tianeptine stocks to a DEA-registered person before the effective date of the final scheduling action. Any required disposal must follow 21 CFR part 1317 and other applicable laws.
Research Continuation Window: 90 Days
If finalized, researchers already registered to conduct research with another Schedule I substance may continue research on tianeptine only if they submit a completed application for registration or modification no later than 90 calendar days after the date the final rule takes effect. Continued research can proceed until the application is withdrawn or DEA serves an order to show cause; expedited hearings, if requested, would be held not later than 45 calendar days after the request.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
Previous / Next Documents
Previous: 2026-13809, Fisheries of the Northeastern United States; Omnibus Management Flexibility Amendment to New England Fishery Management Council Fishery Management Plans
The New England Fishery Management Council wants to make fishing rules more flexible and easier to adjust during the season. This change affects fishermen and managers working with 27 fish species along the Northeast coast. Comments are open until August 7, 2026, so get ready to weigh in on how these updates could help keep fishing smart and steady without extra costs.
Next: C1-2026-12542, Naturalization Application Fee Adjustments
Starting soon, people applying to become U.S. citizens might see some changes in the fees they pay. If you can’t afford the fee, you can ask for a waiver using a special form that helps speed up the decision. This update affects individuals and households applying for naturalization and aims to make fee waivers clearer and faster.